Success Metrics

Clinical Success Rate

60.0%

Based on 6 completed trials

Completion Rate

60%(6/10)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

4(31%)

Phase Distribution

Ph phase_1

Ph phase_4

15%

Ph not_applicable

Ph phase_2

54%

Ph phase_3

15%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution13 total trials

Phase 1Safety & dosage

1(7.7%)

Phase 2Efficacy & side effects

7(53.8%)

Phase 3Large-scale testing

2(15.4%)

Phase 4Post-market surveillance

2(15.4%)

N/ANon-phased studies

1(7.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

54.5%

6 of 11 finished

Non-Completion Rate

45.5%

5 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(6)

Terminated(5)

Other(1)

Detailed Status

Completed6

Terminated4

Withdrawn1

Not yet recruiting1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

60.0%

Most Advanced

Phase 4

Trials by Phase

Phase 11 (7.7%)

Phase 27 (53.8%)

Phase 32 (15.4%)

Phase 42 (15.4%)

N/A1 (7.7%)

Trials by Status

withdrawn18%

completed646%

not_yet_recruiting18%

unknown18%

terminated431%

Recent Activity

0 active trials

Showing 5 of 13

not_yet_recruitingphase_2

The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy

NCT07475065

completedphase_4

Comparing Oral Lumbrokinase DLBS1033 and Betahistine Mesylate in Benign Paroxysmal Positional Vertigo

NCT07075289

terminatedphase_2

Clinical Trials (13)

Showing 13 of 13 trials

NCT07475065Phase 2

The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy

Not Yet Recruiting

NCT07075289Phase 4

Comparing Oral Lumbrokinase DLBS1033 and Betahistine Mesylate in Benign Paroxysmal Positional Vertigo

Completed

NCT02133521Phase 2

DLBS1033 for Acute Ischemic Stroke Patients

Terminated

NCT02976701Phase 2

Effect of DLBS1033 After Primary PCI in Patients With STE-ACS

Terminated

NCT04425590Phase 2

The Benefit of Add On DLBS1033 for Ischemic Stroke Patient

Unknown

NCT02145988Phase 2

DLBS1033 Treatment in Diabetic With Peripheral Arterial Disease

Terminated

NCT01694537Phase 2

The Effects of DLBS1033 on Haemostasis Parameters in Healthy Volunteers

Completed

NCT01905878Phase 1

Biological Half Life of DLBS1033 in Healthy Volunteers

Completed

NCT02362984Phase 3

DLBS1033 for the Treatment of Acute Ischemic Stroke

Terminated

NCT01865474Phase 4

Efficacy and Safety of DLBS1033 in Subjects With Type 2 Diabetes Mellitus

Completed

NCT02146664Phase 2

DLBS1033 for Acute NSTEMI Without Early Coronary Revascularization

Withdrawn

NCT01790997Phase 3

Efficacy of DLBS1033 in Patients With Acute Ischemic Stroke

Completed

NCT01378585Not Applicable

Safety and Efficacy of DLBS1033 in Healthy Subjects

Completed

All 13 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 13